Hormone response in ovarian cancer: time to reconsider as a clinical target?

被引：115

作者：

Modugno, Francesmary ^{[1
,2
,3
,4
]}

Laskey, Robin ^{[3
,4
,5
]}

Smith, Ashlee L. ^{[5
]}

Andersen, Courtney L. ^{[3
,4
,6
]}

Haluska, Paul ^{[7
]}

Oesterreich, Steffi ^{[3
,4
,8
]}

机构：

[1] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA

[3] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA

[4] Womens Canc Res Ctr, Magee Womens Res Inst, Pittsburgh, PA 15213 USA

[5] UPMC, Div Gynecol Oncol, Magee Womens Hosp, Pittsburgh, PA USA

[6] Univ Pittsburgh, Grad Program Mol Pharmacol, Pittsburgh, PA 15213 USA

[7] Mayo Clin, Div Med Oncol, Rochester, MN USA

[8] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA

来源：

关键词：

ESTROGEN-RECEPTOR-BETA; PHASE-II TRIAL; DOSE MEGESTROL-ACETATE; MESSENGER-RNA EXPRESSION; EPIDERMAL-GROWTH-FACTOR; MEMBRANE PROGESTERONE-RECEPTORS; COOPERATIVE-ONCOLOGY-GROUP; CLEAR-CELL ADENOCARCINOMA; ORAL-CONTRACEPTIVE USE; EPITHELIAL OVARIAN;

D O I：

10.1530/ERC-12-0175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is the sixth most common cancer worldwide among women in developed countries and the most lethal of all gynecologic malignancies. There is a critical need for the introduction of targeted therapies to improve outcome. Epidemiological evidence suggests a critical role for steroid hormones in ovarian tumorigenesis. There is also increasing evidence from in vitro studies that estrogen, progestin, and androgen regulate proliferation and invasion of epithelial ovarian cancer cells. Limited clinical trials have shown modest response rates; however, they have consistently identified a small subset of patients that respond very well to endocrine therapy with few side effects. We propose that it is timely to perform additional well-designed trials that should include biomarkers of response. Endocrine-Related Cancer (2012) 19 R255-R279

引用

页码：R255 / R279

页数：25

共 236 条

[1]

AABO K, 1982, CANCER TREAT REP, V66, P407

[2] HORMONAL PALLIATION OF CHEMORESISTANT OVARIAN-CANCER - 3 CONSECUTIVE PHASE-II TRIALS OF THE MID-ATLANTIC ONCOLOGY PROGRAM [J].

AHLGREN, JD ;

ELLISON, NM ;

GOTTLIEB, RJ ;

LALUNA, F ;

LOKICH, JJ ;

SINCLAIR, PR ;

UENO, W ;

WAMPLER, GL ;

YEUNG, KY ;

ALT, D ;

FRYER, JG .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :1957-1968

[3] Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors [J].

Akahira, J ;

Suzuki, T ;

Ito, K ;

Kaneko, C ;

Darnel, AD ;

Moriya, T ;

Okamura, K ;

Yaegashi, N ;

Sasano, H .

JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (07) :807-815

[4] G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells [J].

Albanito, Lidia ;

Madeo, Antonio ;

Lappano, Rosamaria ;

Vivacqua, Adele ;

Rago, Vittoria ;

Carpino, Amalia ;

Oprea, Tudor I. ;

Prossnitz, Eric R. ;

Musti, Anna Maria ;

Ando, Sebastiano ;

Maggiolini, Marcello .

CANCER RESEARCH, 2007, 67 (04) :1859-1866

[5] Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures - The Women's Health Initiative randomized trial [J].

Anderson, GL ;

Judd, HL ;

Kaunitz, AM ;

Barad, DH ;

Beresford, SAA ;

Pettinger, M ;

Liu, J ;

McNeeley, SG ;

Lopez, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (13) :1739-1748

[6]

[Anonymous], J CLIN ONCOLOGY

[7]

[Anonymous], INT J GYNECOLOGIC S1

[8]

[Anonymous], P AM SOC CLIN ONCOLO

[9]

[Anonymous], ASCO ANN M

[10]

[Anonymous], AM J OBSTET GYNECOLO

← 1 2 3 4 5 6 7 8 9 10 →